JP2022535924A5 - - Google Patents
Info
- Publication number
- JP2022535924A5 JP2022535924A5 JP2021572583A JP2021572583A JP2022535924A5 JP 2022535924 A5 JP2022535924 A5 JP 2022535924A5 JP 2021572583 A JP2021572583 A JP 2021572583A JP 2021572583 A JP2021572583 A JP 2021572583A JP 2022535924 A5 JP2022535924 A5 JP 2022535924A5
- Authority
- JP
- Japan
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2025050785A JP2025111446A (ja) | 2019-06-06 | 2025-03-25 | 腫瘍活性化ｔ細胞エンゲージャーに関する組成物および方法 |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962858254P | 2019-06-06 | 2019-06-06 | |
| US62/858,254 | 2019-06-06 | ||
| US202062978662P | 2020-02-19 | 2020-02-19 | |
| US62/978,662 | 2020-02-19 | ||
| PCT/US2020/036493 WO2020247871A2 (en) | 2019-06-06 | 2020-06-05 | Compositions and methods relating to tumor activated t cell engagers |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025050785A Division JP2025111446A (ja) | 2019-06-06 | 2025-03-25 | 腫瘍活性化ｔ細胞エンゲージャーに関する組成物および方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022535924A JP2022535924A (ja) | 2022-08-10 |
| JP2022535924A5 true JP2022535924A5 (https=) | 2023-06-09 |
| JPWO2020247871A5 JPWO2020247871A5 (https=) | 2023-06-09 |
Family
ID=73652312
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021572583A Pending JP2022535924A (ja) | 2019-06-06 | 2020-06-05 | 腫瘍活性化ｔ細胞エンゲージャーに関する組成物および方法 |
| JP2025050785A Pending JP2025111446A (ja) | 2019-06-06 | 2025-03-25 | 腫瘍活性化ｔ細胞エンゲージャーに関する組成物および方法 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2025050785A Pending JP2025111446A (ja) | 2019-06-06 | 2025-03-25 | 腫瘍活性化ｔ細胞エンゲージャーに関する組成物および方法 |
Country Status (6)
| Country | Link |
|---|---|
| US (3) | US20230220105A1 (https=) |
| EP (1) | EP3980131A4 (https=) |
| JP (2) | JP2022535924A (https=) |
| KR (1) | KR20220052898A (https=) |
| CN (1) | CN114423499A (https=) |
| WO (2) | WO2020247871A2 (https=) |
Families Citing this family (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20200385440A1 (en) * | 2017-12-07 | 2020-12-10 | Janux Therapeutics, Inc. | Modified bispecific t cell receptors |
| IL322315A (en) | 2019-05-14 | 2025-09-01 | Provention Bio Inc | Methods and preparations for preventing type 1 diabetes |
| JP2024518539A (ja) * | 2020-04-04 | 2024-05-01 | ジャナックス セラピューティクス，インク． | 抗体を標的とする腫瘍によって活性化されるｅｇｆｒおよびエフェクター細胞抗原に関する組成物および方法 |
| AU2021287998B2 (en) | 2020-06-11 | 2026-03-12 | Benaroya Research Institute At Virginia Mason | Methods and compositions for preventing type 1 diabetes |
| WO2022035866A1 (en) | 2020-08-11 | 2022-02-17 | Janux Therapeutics, Inc. | Cleavable linker compositions and methods |
| AU2021396172A1 (en) | 2020-12-09 | 2023-07-06 | Janux Therapeutics, Inc. | Compositions and methods related to tumor activated antibodies targeting psma and effector cell antigens |
| CN114656562B (zh) * | 2020-12-23 | 2023-11-03 | 北京天广实生物技术股份有限公司 | 结合人和猴cd3的抗体及其应用 |
| EP4337794A4 (en) * | 2021-05-11 | 2025-07-02 | Janux Therapeutics Inc | ANTIBODIES TARGETING EGFR AND CD3 AND THEIR USES |
| US12565529B2 (en) | 2021-05-24 | 2026-03-03 | Provention Bio, Inc. | Methods for treating type 1 diabetes |
| EP4519326A1 (en) * | 2022-05-04 | 2025-03-12 | Janux Therapeutics, Inc. | Tumor activated multispecific antibodies for targeting cd28 and pd-l1 and methods of use thereof |
| KR20250051722A (ko) * | 2022-08-18 | 2025-04-17 | 이뮤노코어 리미티드 | 멀티-도메인 결합 분자 |
| CN121443645A (zh) * | 2023-05-03 | 2026-01-30 | 佳努克斯治疗公司 | 靶向cd3的肿瘤活化的抗体及其用途 |
| WO2025085855A2 (en) * | 2023-10-20 | 2025-04-24 | BioNTech SE | Multispecific t cell engagers compositions and methods of use thereof |
| WO2025085862A2 (en) * | 2023-10-20 | 2025-04-24 | BioNTech SE | Multispecific t cell engagers compositions and methods of use thereof |
| GB2641580A (en) * | 2024-06-07 | 2025-12-10 | T Therapeutics Ltd | Tumour-transforming multispecific proteins |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20010031264A1 (en) * | 1996-01-25 | 2001-10-18 | Andrew Segal | Vaccine compositions and methods of modulating immune responses |
| BRPI0713421A2 (pt) * | 2006-06-14 | 2012-03-13 | Imclone Systems Incorporated | Formulação liofolizada, formulação aquosa adequada para a liofilização, e, métodos para estabilizar am anticorpo e para tratar um mamífero |
| RS53008B2 (sr) * | 2007-04-03 | 2022-12-30 | Amgen Res Munich Gmbh | Interspecijski specifičan cd3-epsilon vezujući domen |
| US20110214199A1 (en) * | 2007-06-06 | 2011-09-01 | Monsanto Technology Llc | Genes and uses for plant enhancement |
| AU2008328726B2 (en) * | 2007-11-30 | 2014-06-12 | Glaxo Group Limited | Antigen-binding constructs |
| GB0911566D0 (en) * | 2009-07-03 | 2009-08-12 | Immunocore Ltd | T cell receptors |
| WO2013041865A1 (en) * | 2011-09-22 | 2013-03-28 | Immunocore Limited | T cell receptors |
| CN104540518A (zh) * | 2012-04-27 | 2015-04-22 | 西托姆克斯治疗公司 | 结合表皮生长因子受体的可活化的抗体其使用方法 |
| CN104271602B (zh) * | 2012-11-21 | 2020-08-21 | 武汉友芝友生物制药有限公司 | 双特异性抗体 |
| IL270562B (en) * | 2014-01-31 | 2022-08-01 | Cytomx Therapeutics Inc | Polypeptide substrates that activate matriptase and u-plasminogen and other cleavable groups, preparations containing them and their uses |
| JP7020909B2 (ja) * | 2014-07-25 | 2022-02-16 | シトムクス セラピューティクス，インコーポレイティド | 抗－ｃｄ３抗体、活性化可能抗－ｃｄ３抗体、多重特異的抗－ｃｄ３抗体、多重特異的活性化可能抗－ｃｄ３抗体、及びそれらの使用方法 |
| MA41374A (fr) * | 2015-01-20 | 2017-11-28 | Cytomx Therapeutics Inc | Substrats clivables par métalloprotéase matricielle et clivables par sérine protéase et procédés d'utilisation de ceux-ci |
| WO2016210447A1 (en) * | 2015-06-26 | 2016-12-29 | University Of Southern California | Masking chimeric antigen receptor t cells for tumor-specific activation |
| JP7038353B2 (ja) * | 2016-04-13 | 2022-03-18 | ヴィヴィア バイオテック，エス．エル | エクスビボのｂｉｔｅ活性化ｔ細胞 |
| JP7101621B2 (ja) * | 2016-05-20 | 2022-07-15 | ハープーン セラピューティクス，インク． | 単一ドメイン血清アルブミン結合タンパク質 |
| CA3287794A1 (en) * | 2017-10-14 | 2025-10-27 | Cytomx Therapeutics, Inc. | Antibodies, activatable antibodies, bispecific antibodies, and bispecific activatable antibodies and methods of use thereof |
| KR20210020903A (ko) * | 2018-05-14 | 2021-02-24 | 하푼 테라퓨틱스, 인크. | 면역글로불린 분자의 조건부 활성화를 위한 결합 모이어티 |
-
2020
- 2020-06-05 CN CN202080056153.1A patent/CN114423499A/zh active Pending
- 2020-06-05 WO PCT/US2020/036493 patent/WO2020247871A2/en not_active Ceased
- 2020-06-05 WO PCT/US2020/036489 patent/WO2020247867A2/en not_active Ceased
- 2020-06-05 KR KR1020227000224A patent/KR20220052898A/ko active Pending
- 2020-06-05 JP JP2021572583A patent/JP2022535924A/ja active Pending
- 2020-06-05 EP EP20819457.1A patent/EP3980131A4/en active Pending
- 2020-06-05 US US17/616,278 patent/US20230220105A1/en active Pending
- 2020-06-05 US US17/616,281 patent/US20230220109A1/en active Pending
-
2024
- 2024-07-26 US US18/785,900 patent/US20240376226A1/en not_active Abandoned
-
2025
- 2025-03-25 JP JP2025050785A patent/JP2025111446A/ja active Pending